Honored for capabilities, compatibility and expertise provided to
biopharmaceutical companies
WILMINGTON, N.C.–(BUSINESS WIRE)–Pharmaceutical Product Development, LLC (PPD)
has been recognized for excellence in clinical research for the eighth
consecutive year by pharmaceutical and biotech executives surveyed for Life
Science Leader magazine’s 2019
CRO Leadership Awards.
PPD earned honors in three distinct categories of clinical research,
including for its capabilities, compatibility and expertise. The
recognition is based on survey responses from biopharmaceutical industry
leaders responsible for making or influencing decisions to collaborate
with contract research organizations (CROs) on clinical development
programs.
In addition, based on data from a separate market survey of pharma
companies, PPD was recognized with an individual attribute award for
providing clients with robust data analytics technology to inform
decision-making in clinical research.
“At PPD, we are committed to accelerating our customers’ promising
medicines from early development through regulatory approval and market
access by generating evidence to demonstrate effectiveness, safety and
value,” said David Simmons, chairman and CEO of PPD. “We leverage data
analytics, patient-centered strategies and the passion of our people for
improving health. Their talent, ingenuity and commitment are our formula
for extraordinary results. Our clients can rely on us for quality
performance, continual innovation and trusted partnership.”
The Life Science Leader 2019 CRO Leadership Awards were based on
surveys, encompassing 27 performance metrics, conducted by Industry
Standard Research, a full-service pharmaceutical market research
firm, to help the publication assess the performance of CROs.
About PPD
PPD is a leading global contract research organization providing
comprehensive, integrated drug development, laboratory and lifecycle
management services. Our clients and partners include pharmaceutical,
biotechnology, medical device, academic and government organizations.
With offices in 48 countries and more than 21,000 professionals
worldwide, PPD applies innovative technologies, therapeutic expertise
and a firm commitment to quality to help clients and partners bend the
cost and time curve of drug development and optimize value in delivering
life-changing therapies to improve health. For more information, visit www.ppdi.com.
Contacts
Media:
Randy Buckwalter
+1 919 456 4425
randy.buckwalter@ppdi.com
Investors:
Nate Speicher
+1 910 558 6783
nate.speicher@ppdi.com